{
    "id": 29070,
    "fullName": "EGFR V769_D770insASV",
    "impact": "insertion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EGFR V769_D770insASV results in the insertion of three amino acids in the protein kinase domain of the Egfr protein between amino acids 769 and 770 (UniProt.org). V769_D770insASV has not been biochemically characterized, but is predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",
            "references": [
                {
                    "id": 440,
                    "pubMedId": 24353160,
                    "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24353160"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "V769_D770insASV",
    "createDate": "12/07/2018",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": {
        "id": 178324,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55181317_55181318insCAAGCGTAG",
        "cDna": "c.2308_2309insCAAGCGTAG",
        "protein": "p.A767_V769dupASV",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19354,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived xenograft lung cancer cell line harboring EGFR V769_D770insASV demonstrated sensitivity to TAS6417 in culture (PMID: 31467113).",
            "molecularProfile": {
                "id": 30999,
                "profileName": "EGFR V769_D770insASV"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16160,
                    "pubMedId": 31467113,
                    "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31467113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19356,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited viability of a transformed cell line expressing EGFR V769_D770insASV in culture (PMID: 31467113).",
            "molecularProfile": {
                "id": 30999,
                "profileName": "EGFR V769_D770insASV"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16160,
                    "pubMedId": 31467113,
                    "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31467113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15398,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Luminespib (AUY922) treatment demonstrated safety and efficacy in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, with 1 patient harboring EGFR V769_D770insASV achieved stable disease (PMID: 30351341; NCT01854034).",
            "molecularProfile": {
                "id": 30999,
                "profileName": "EGFR V769_D770insASV"
            },
            "therapy": {
                "id": 647,
                "therapyName": "Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13126,
                    "pubMedId": 30351341,
                    "title": "Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30351341"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19362,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed cell line expressing EGFR V769_D770insASV was resistant to Tarceva (erlotinib) in culture (PMID: 31467113).",
            "molecularProfile": {
                "id": 30999,
                "profileName": "EGFR V769_D770insASV"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16160,
                    "pubMedId": 31467113,
                    "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31467113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30999,
            "profileName": "EGFR V769_D770insASV",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 178324,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55181317_55181318insCAAGCGTAG",
            "cDna": "c.2308_2309insCAAGCGTAG",
            "protein": "p.A767_V769dupASV",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}